Loading...
Chemotherapy-induced thrombocytopenia (CIT) is a common complication that can cause bleeding, require reduced chemotherapy intensity, and potentially worsen outcomes. Thrombopoietin agonists are approved for thrombocytopenia in many other indications, but robust data for CIT have been lacking. Now, researchers have conducted an industry-sponsored, global, phase 3 trial, randomizing 165 patients (75% with colorectal cancer, 68% with stage IV disease) to receive romiplostim (109 patients) or placebo (56 patients) for 3 chemotherapy cycles. Of the participants, 63% received 5-fluorouracil, leucovorin, and oxaliplatin and 73% had received <2 prior lines of chemotherapy. The primary end point was absence of CIT-induced chemotherapy dose m…